# A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma

> **NCT07099391** · PHASE1,PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 65 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Dara-RVd
- **DRUG:** Tec-RVd

## Key facts

- **NCT ID:** NCT07099391
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-24
- **Primary completion:** 2029-07-24
- **Final completion:** 2029-07-24
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07099391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07099391, "A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07099391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*